Skip to main content

Table 1 Age-standardized incidence rates and average annual percent change by sex, cancer site, and subtype with male-to-female (M/F) rate ratios and rate differences, France

From: Cancer incidence and mortality trends in France over 1990–2018 for solid tumors: the sex gap is narrowing

 

Men

Women

M/F

Age standardized ratesa

Average annual percent change (AAPC) [95% CIb]

Age standardized ratesa

Average annual percent change (AAPC) [95% CIb]

Relative differences

Absolute differences

Rate ratios [95% CIb]

Percent change in rate ratios

Rate differences

Points of change in rate differences

Cancer site or subtype

1990

2018

1990-2018

1990

2018

1990-2018

1990

2018

1990-2018

1990

2018

1990-2018

All cancers (including hematological malignancies)

320.7

330.2

0.1 [0.1; 0.2]

200.6

274.0

1.1 [1.1; 1.2]

1.6 [1.5;1.7]

1.2 [1.2;1.3]

-25%

120.1

56.2

-63.9

Lip, oral cavity and pharynx

38.6

18.3

-2.6 [-2.8; -2.5]

3.5

5.8

1.8 [1.5; 2.1]

10.9 [9.6;12.4]

3.1 [2.8;3.6]

-72%

35.1

12.5

-22.6

Esophagus

14.7

6.8

-2.7 [-3; -2.5]

1.2

1.5

0.9 [0.5; 1.3]

12.6 [10.6;15.1]

4.5 [3.8;5.4]

-64%

13.5

5.3

-8.2

 Adenocarcinomas

1.2

2.8

2.9 [2.5; 3.4]

0.1

0.3

1.9 [0.9; 2.8]

8.3 [6.6;10.4]

11 [8.8;13.7]

33%

1.1

2.5

1.4

 Squamous cell carcinomas

12.8

3.9

-4.1 [-4.4; -3.9]

0.9

1.2

0.9 [0.3; 1.4]

13.6 [11;16.7]

3.3 [2.6;4.1]

-76%

11.9

2.7

-9.2

Stomach

12.2

6.3

-2.3 [-2.5;-2.1]

4.6

2.7

-1.9 [-2.2; -1.6]

2.7 [2.4;3]

2.4 [2.1;2.7]

-11%

7.6

3.6

-4.0

Colon-rectum

40.0

34.0

-0.6 [-0.7; -0.5]

24.0

23.9

0 [-0.1; 0.1]

1.7 [1.6;1.7]

1.4 [1.3;1.5]

-18%

16.0

10.1

-5.9

 Colon

22.6

20.7

-0.3 [-0.4; -0.2]

15.1

14.8

-0.1 [-0.2; 0.1]

1.5 [1.4;1.6]

1.4 [1.3;1.5]

-7%

7.5

5.9

-1.6

 Rectum

17.0

12.7

-1.0 [-1.2; -0.9]

8.1

6.9

-0.5 [-0.7; -0.3]

2.1 [2;2.2]

1.8 [1.7;2]

-14%

8.9

5.8

-3.1

 Anus

0.5

0.8

1.5 [0.7; 2.2]

0.9

2.4

3.4 [2.9; 3.9]

0.6 [0.5;0.7]

0.3 [0.3;0.4]

-50%

-0.4

-1.6

-1.2

Liver

8.0

12.5

1.6 [1.4; 1.8]

1.1

2.9

3.5 [3.1; 3.9]

7.4 [6.3;8.7]

4.4 [3.8;5.1]

-41%

6.9

9.6

2.7

Pancreas

5.2

11

2.7 [2.5; 2.9]

2.7

7.7

3.8 [3.6; 4.1]

2 [1.8;2.1]

1.4 [1.3;1.6]

-30%

2.5

3.3

0.8

Larynx

11.6

4.8

-3.1 [-3.4; -2.8]

0.7

0.7

0 [NC]c

17.1 [15.5;18.9]

7.1 [6.3;7.9]

-58%

10.9

4.1

-6.8

Lung

51.8

50.5

-0.1 [-0.2; 0]

5.4

23.2

5.3 [5.1; 5.5]

9.5 [8.6;10.5]

2.2 [2;2.4]

-77%

46.4

27.3

-19.1

 Adenocarcinomas

8.9

26.2

3.9 [3.7; 4.1]

1.9

15.1

7.7 [7.4; 8.1]

4.7 [4.2;5.3]

1.7 [1.6;1.9]

-64%

7.0

11.1

4.1

 Squamous cell carcinomas

25.9

11.3

-2.9 [-3.1; -2.7]

1.4

2.4

2.1 [1.6; 2.6]

19.1 [16.4;22.4]

4.7 [4;5.5]

-75%

24.5

8.9

-15.6

 Small cell carcinomas

7.1

5.5

-0.9 [-1.2; -0.6]

0.8

2.7

4.4 [3.9; 5]

8.8 [7.5;10.5]

2 [1.7;2.4]

-77%

6.3

2.8

-3.5

Skin melanoma

4.8

14.2

4.0 [3.7; 4.2]

6.7

14.2

2.7 [2.5; 3]

0.7 [0.6;0.8]

1 [0.9;1.1]

43%

-1.9

0.0

1.9

Breast

-

-

-

72.8

99.9

1.1 [1; 1.2]

-

-

-

-

-

-

Cervix uteris

-

-

-

10.2

6.1

-1.8 [-2.1; -1.5]

-

-

-

-

-

-

Corpus uteri

-

-

-

10.6

11

0.1 [-0.1; 0.3]

-

-

-

-

-

-

Ovary

-

-

-

9.9

7.5

-1.0 [-1.2; -0.8]

-

-

-

-

-

-

Prostate

47.2

81.5d

2.2 d [2.1; 1.3]

-

-

-

-

-

-

-

-

-

Testis

4.3

8.7

2.6 [2.2; 2.9]

-

-

-

-

-

-

-

-

-

Kidney

10.6

17.1

1.7 [1.5; 1.9]

4.8

7.1

1.4 [1.2; 1.7]

2.2 [2;2.5]

2.4 [2.2;2.7]

9%

5.8

10.0

4.2

Urinary bladder

17.2

14.3

-0.7 [-0.8; -0.5]

2.5

2.4

-0.2 [-0.5; 0.1]

6.9 [6.2;7.6]

6.1 [5.4;6.8]

-12%

14.7

11.9

-2.8

Central nervous system

5.3

6.7

0.8 [0.6; 1.1]

3.7

4.5

0.6 [0.3; 1]

1.4 [1.3;1.5]

1.5 [1.4;1.6]

7%

1.6

2.2

0.6

Thyroid gland

1.7

5.6

4.4 [3.9; 4.8]

5.6

18.5

4.4 [4.1; 4.6]

0.3 [0.2;0.4]

0.3 [0.2;0.4]

0%

-3.9

-12.9

-9.0

  1. aIncidence rates are expressed per 100,000 population and age-standardized to the 1960 standard world population (95% confidence intervals are reported in Supplementary Table S5)
  2. bCI: confidence interval
  3. cNC: 95% CI not calculable because the selected model does not include an effect for the year; p-value difference of AAPCs (men vs. women) not calculable either
  4. dIncidence indicators for prostate cancer relate to 2015 (last year of observation) and not 2018 (see specific Materials and Methods), and thus the AAPC cover period 1990–2015 or 2010–2015, respectively